Quidel Corp
F:QL1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (38.8), the stock would be worth €54.41 (33% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 58 | €81.28 |
0%
|
| 3-Year Average | 38.8 | €54.41 |
-33%
|
| 5-Year Average | 20.9 | €29.35 |
-64%
|
| Industry Average | 19.2 | €26.97 |
-67%
|
| Country Average | 19.6 | €27.49 |
-66%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€3.8B
|
/ |
Dec 2025
$54.8m
|
= |
|
|
€3.8B
|
/ |
Dec 2025
$390.2m
|
= |
|
|
€3.8B
|
/ |
Dec 2026
$404.3m
|
= |
|
|
€3.8B
|
/ |
Dec 2027
$471.3m
|
= |
|
|
€3.8B
|
/ |
Dec 2028
$511.5m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Quidel Corp
F:QL1
|
875.2m EUR | 58 | -0.8 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 34.1 | 39.1 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
63.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.5B CHF | 29.1 | 39 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
98.2B DKK | 15.5 | 24.6 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.7B USD | 20 | 33.3 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP | 18.9 | 34.9 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.9B USD | 56.2 | -16.4 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
895.2B JPY | 32.6 | 50.6 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.4T KRW | -80.5 | -38 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.4B USD | 18.2 | 23.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Quidel Corp
Glance View
Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.